[
  {
    "ts": null,
    "headline": "Eli Lilly's GLP-1 pill could be the next key in obesity treatment",
    "summary": "Eli Lilly (LLY) will soon be releasing trial data on its small-molecule GLP-1 weight-loss pill, Orforglipron. The drug could be pivotal for the obesity treatment market due to its accessibility. Evan Seigerman, BMO Capital Markets managing director of biopharma equity research, joins Market Domination hosts Julie Hyman and Josh Lipton to share insights on the upcoming data release, supply chain challenges, and patient adherence issues. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
    "url": "https://finnhub.io/api/news?id=c6127959358ae451561acf9443003a60d7ba2296e97308430042bfe0a61833c1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743023071,
      "headline": "Eli Lilly's GLP-1 pill could be the next key in obesity treatment",
      "id": 133462035,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) will soon be releasing trial data on its small-molecule GLP-1 weight-loss pill, Orforglipron. The drug could be pivotal for the obesity treatment market due to its accessibility. Evan Seigerman, BMO Capital Markets managing director of biopharma equity research, joins Market Domination hosts Julie Hyman and Josh Lipton to share insights on the upcoming data release, supply chain challenges, and patient adherence issues. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
      "url": "https://finnhub.io/api/news?id=c6127959358ae451561acf9443003a60d7ba2296e97308430042bfe0a61833c1"
    }
  },
  {
    "ts": null,
    "headline": "US is only country debating GLP-1 insurance coverage for weight loss: Cigna CEO Cordani",
    "summary": "Cigna (CI) CEO David Cordani is not convinced of the benefits of GLP-1s for weight-loss patients and said the US is the only country among developed nations where insurance coverage is being debated.",
    "url": "https://finnhub.io/api/news?id=64ce262c8731e0be72f6af4537f8d5b7c4747e2b9729830330fffd82f81d4f50",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743019988,
      "headline": "US is only country debating GLP-1 insurance coverage for weight loss: Cigna CEO Cordani",
      "id": 133462036,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Cigna (CI) CEO David Cordani is not convinced of the benefits of GLP-1s for weight-loss patients and said the US is the only country among developed nations where insurance coverage is being debated.",
      "url": "https://finnhub.io/api/news?id=64ce262c8731e0be72f6af4537f8d5b7c4747e2b9729830330fffd82f81d4f50"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY): One of Two Sigma Investments’ Top Stock Picks",
    "summary": "We recently published a list of Top 10 Stocks to Buy According to Two Sigma Investments. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other top stocks to buy according to Two Sigma Investments. Two Sigma Investments, LP, a New York City-based hedge fund, […]",
    "url": "https://finnhub.io/api/news?id=389d4d1bbc060e4cd4090de283b6ea95aef837490b7c7c34a053f7dd142482cc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743014468,
      "headline": "Eli Lilly and Company (LLY): One of Two Sigma Investments’ Top Stock Picks",
      "id": 133462037,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published a list of Top 10 Stocks to Buy According to Two Sigma Investments. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other top stocks to buy according to Two Sigma Investments. Two Sigma Investments, LP, a New York City-based hedge fund, […]",
      "url": "https://finnhub.io/api/news?id=389d4d1bbc060e4cd4090de283b6ea95aef837490b7c7c34a053f7dd142482cc"
    }
  },
  {
    "ts": null,
    "headline": "Viking Therapeutics Skids Despite 'Rapid' Enrollment In Obesity Pill Study",
    "summary": "Viking Therapeutics stock skidded Wednesday despite the \"encouraging\" speed with which the company enrolled patients in an obesity study.",
    "url": "https://finnhub.io/api/news?id=0d4f518ba7629572f6a60fb8e820a28959a9985ee76efc4701cb171d672ac5eb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743007416,
      "headline": "Viking Therapeutics Skids Despite 'Rapid' Enrollment In Obesity Pill Study",
      "id": 133458288,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Viking Therapeutics stock skidded Wednesday despite the \"encouraging\" speed with which the company enrolled patients in an obesity study.",
      "url": "https://finnhub.io/api/news?id=0d4f518ba7629572f6a60fb8e820a28959a9985ee76efc4701cb171d672ac5eb"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock underperforms Wednesday when compared to competitors",
    "summary": "Eli Lilly & Co. stock underperforms Wednesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=1c762dd625d67f2dd78f4511c02b871aad98fcd82d7498511c181a50b151bb64",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743006660,
      "headline": "Eli Lilly & Co. stock underperforms Wednesday when compared to competitors",
      "id": 133463010,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock underperforms Wednesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=1c762dd625d67f2dd78f4511c02b871aad98fcd82d7498511c181a50b151bb64"
    }
  },
  {
    "ts": null,
    "headline": "Franklin Growth Opportunities Fund Q4 2024 Commentary",
    "summary": "US stocks collectively rose in the fourth quarter of 2024, with the S&P 500 Index, Dow Jones Industrial Average and NASDAQ Composite Index reaching new record highs.",
    "url": "https://finnhub.io/api/news?id=826ddcf2b816d7f94d478f285163d5524026b26fe06f36a5cf4101ba2c492472",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743000900,
      "headline": "Franklin Growth Opportunities Fund Q4 2024 Commentary",
      "id": 133459262,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2189183736/image_2189183736.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "US stocks collectively rose in the fourth quarter of 2024, with the S&P 500 Index, Dow Jones Industrial Average and NASDAQ Composite Index reaching new record highs.",
      "url": "https://finnhub.io/api/news?id=826ddcf2b816d7f94d478f285163d5524026b26fe06f36a5cf4101ba2c492472"
    }
  },
  {
    "ts": null,
    "headline": "The Risk/Reward Of Avidity Biosciences And Its 2 Promising Programs",
    "summary": "Avidity Biosciences, Inc.'s innovative AOC platform and promising clinical programs make it a high-risk, high-reward investment. Read more on RNA stock update.",
    "url": "https://finnhub.io/api/news?id=e9c604309b041827af4cb535b2f3a76212b25575ce814704f2600525c158cd74",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742984229,
      "headline": "The Risk/Reward Of Avidity Biosciences And Its 2 Promising Programs",
      "id": 133456250,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/155151969/image_155151969.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Avidity Biosciences, Inc.'s innovative AOC platform and promising clinical programs make it a high-risk, high-reward investment. Read more on RNA stock update.",
      "url": "https://finnhub.io/api/news?id=e9c604309b041827af4cb535b2f3a76212b25575ce814704f2600525c158cd74"
    }
  },
  {
    "ts": null,
    "headline": "2 No-Brainer Growth Stocks to Buy and Hold Forever",
    "summary": "Don't let market volatility convince you otherwise: Investing in stocks remains one of the best ways to accumulate capital over long periods.  Companies that can last -- and thrive -- that long are rare, but let's consider two brilliant examples investors should strongly consider today: Eli Lilly (NYSE: LLY) and Shopify (NYSE: SHOP).  Eli Lilly, a leading pharmaceutical company, develops and markets therapies across various areas, including immunology, oncology, and especially endocrine disorders like diabetes.",
    "url": "https://finnhub.io/api/news?id=21479c5be8be2fd71afd5abedb20ba136698b09cab2af9f24f115725d85ebd9c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742983500,
      "headline": "2 No-Brainer Growth Stocks to Buy and Hold Forever",
      "id": 133448330,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Don't let market volatility convince you otherwise: Investing in stocks remains one of the best ways to accumulate capital over long periods.  Companies that can last -- and thrive -- that long are rare, but let's consider two brilliant examples investors should strongly consider today: Eli Lilly (NYSE: LLY) and Shopify (NYSE: SHOP).  Eli Lilly, a leading pharmaceutical company, develops and markets therapies across various areas, including immunology, oncology, and especially endocrine disorders like diabetes.",
      "url": "https://finnhub.io/api/news?id=21479c5be8be2fd71afd5abedb20ba136698b09cab2af9f24f115725d85ebd9c"
    }
  },
  {
    "ts": null,
    "headline": "Foghorn: SMARCA4 Targeting Brings About Treating Up To 10% Of NSCLC Patients",
    "summary": "Foghorn Therapeutics advances FHD-909 for SMARCA4 tumors, backed by Eli Lilly partnership. Read here to know why we are neutral on FHTX stock.",
    "url": "https://finnhub.io/api/news?id=7ca6d1abe07cc7ab333d46c5dcd79ade8fa861404ae3f4681b7986c49dbbc5b0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742959256,
      "headline": "Foghorn: SMARCA4 Targeting Brings About Treating Up To 10% Of NSCLC Patients",
      "id": 133446207,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2196233681/image_2196233681.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Foghorn Therapeutics advances FHD-909 for SMARCA4 tumors, backed by Eli Lilly partnership. Read here to know why we are neutral on FHTX stock.",
      "url": "https://finnhub.io/api/news?id=7ca6d1abe07cc7ab333d46c5dcd79ade8fa861404ae3f4681b7986c49dbbc5b0"
    }
  }
]